ストックスクリーナーアプリを入手
17.03
0.41%
0.07
アフターアワーズ：
17.05
0.02
+0.12%
前日終値:
$16.96
開ける：
$16.9
24時間の取引高:
222.82K
Relative Volume:
0.71
時価総額：
$469.60M
収益：
$11.88M
当期純損益:
$-162.08M
株価収益率:
-1.3641
EPS:
-12.484
ネットキャッシュフロー:
$-156.43M
1週間 パフォーマンス:
-5.39%
1か月 パフォーマンス:
-5.39%
6か月 パフォーマンス:
+55.67%
1年 パフォーマンス:
+11.38%
1日の値動き範囲:
$16.55
$17.36
1週間の範囲:
$16.36
$18.52
52週間の値動き範囲:
$8.72
$27.41
Crescent Biopharma Inc Stock (CBIO) Company Profile
Compare CBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
17.03 | 467.67M | 11.88M | -162.08M | -156.43M | -12.48 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-28 | 開始されました | Piper Sandler | Overweight |
| 2026-01-21 | 開始されました | Guggenheim | Buy |
| 2025-08-25 | 開始されました | Jefferies | Buy |
| 2025-08-11 | 開始されました | H.C. Wainwright | Buy |
| 2025-07-14 | 開始されました | Wedbush | Outperform |
| 2025-06-25 | 開始されました | Stifel | Buy |
| 2025-03-21 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-03-11 | 開始されました | Noble Capital Markets | Outperform |
| 2024-07-26 | ダウングレード | TD Cowen | Buy → Hold |
| 2023-12-22 | 開始されました | CapitalOne | Overweight |
| 2021-11-12 | アップグレード | Jefferies | Hold → Buy |
| 2021-04-29 | 再開されました | Stephens | Overweight |
| 2021-02-10 | 開始されました | Piper Sandler | Overweight |
| 2020-05-21 | 開始されました | Raymond James | Outperform |
| 2019-11-14 | 開始されました | ROTH Capital | Buy |
| 2019-08-05 | ダウングレード | Jefferies | Buy → Hold |
| 2019-08-05 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2019-08-05 | ダウングレード | SunTrust | Buy → Hold |
| 2019-04-12 | 開始されました | Piper Jaffray | Overweight |
| 2019-01-04 | 開始されました | Oppenheimer | Outperform |
| 2018-12-18 | 開始されました | H.C. Wainwright | Buy |
| 2018-02-12 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2018-02-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-12-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-06-12 | 開始されました | Chardan Capital Markets | Buy |
| 2017-06-06 | 開始されました | Ladenburg Thalmann | Buy |
| 2016-07-26 | 開始されました | SunTrust | Buy |
| 2016-06-30 | 開始されました | Rodman & Renshaw | Buy |
| 2015-03-17 | 繰り返されました | Stifel | Buy |
すべてを表示
Crescent Biopharma Inc (CBIO) 最新ニュース
Enterprise value to EBITDA forward of Crescent Biopharma, Inc. – NASDAQ:CBIO - TradingView
Price to sales forward of Crescent Biopharma, Inc. – FWB:C68 - TradingView
ETFs Investing in Crescent Biopharma, Inc. Stocks - TradingView
Crescent Biopharma Inc (CBIO) - MSN
Crescent Biopharma files prospectus for $500M mixed shelf - scanx.trade
Form S-3 Crescent Biopharma Inc For: 1 July By Investing.com - Investing.com Canada
Crescent BiopharmaMay Offer And Sell Up To $500 Million Of SecuritiesSEC Filing - TradingView
Crescent Biopharma (NASDAQ: CBIO) files $500M shelf; $200M ATM with Jefferies - Stock Titan
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell 2000 Index - marketscreener.com
Crescent Biopharma Company Profile & Introduction - Moomoo
Crescent Biopharma(CBIO) Stock Options Chain | Quotes & News - Moomoo
Crescent Biopharma: Intriguing Developer Of ADC/PD1-VEGF Assets May Not Be Sufficiently Derisked - Seeking Alpha
Crescent Biopharma, Inc.(NasdaqCM:CBIO) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Crescent Biopharma, Inc.(NasdaqCM: CBIO) added to Russell Microcap Index - marketscreener.com
CBIOCrescent Biopharma Inc Short Interest - Finviz
Crescent Biopharma, Inc. Actuals & Estimates (NASDAQ:CBIO) - TradingView
Crescent Biopharma Announces Grants of Inducement Awards - GlobeNewswire
CBIO Forecast — Price Target — Prediction for 2027 - TradingView
Crescent Biopharma awards 65,100 options to 3 new hires - Stock Titan
Stifel Nicolaus Reaffirms Their Buy Rating on Crescent Biopharma (CBIO) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO) - The Globe and Mail
Crescent Biopharma CFO Scalzo sells $20,004 in shares By Investing.com - Investing.com UK
Crescent Biopharma general counsel sells $21,911 in shares - Investing.com UK
Crescent Biopharma CEO Joshua Brumm sells $761k in shares By Investing.com - Investing.com India
Crescent Biopharma CFO Scalzo sells $20,004 in shares - Investing.com UK
Crescent Biopharma general counsel sells $21,911 in shares By Investing.com - Investing.com South Africa
Form 4 Crescent Biopharma Inc For: 23 June - Investing.com UK
Crescent Biopharma CEO Joshua Brumm sells $761k in shares - Investing.com UK
Form 4 Crescent Biopharma Inc For: 23 June By Investing.com - Investing.com Nigeria
CRESCENT BIOPHARMA (CBIO) CMO auto-sells shares to cover RSU taxes - Stock Titan
Crescent Biopharma (CBIO) CFO sells 1,112 shares to cover RSU taxes - Stock Titan
Tax-related insider share sale at Crescent Biopharma (CBIO) under Rule 10b5-1 - Stock Titan
CRESCENT BIOPHARMA (CBIO) CSO’s 1,288-share sale covers RSU tax withholding - Stock Titan
Crescent Biopharma (CBIO) insider sale covers taxes on RSU vesting - Stock Titan
Crescent BioPharma (CBIO) COO tax-related sale of 20,549 shares - Stock Titan
Crescent Biopharma (CBIO) CEO’s pre-planned tax sale covers RSU vesting - Stock Titan
Stifel reiterates Crescent Biopharma stock rating on rival trial data By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Crescent Biopharma stock rating - Investing.com
Cantor Fitzgerald reiterates Crescent Biopharma stock rating By Investing.com - Investing.com Nigeria
Stifel reiterates Crescent Biopharma stock rating on rival trial data - Investing.com
Crescent Biopharma Discloses Executive 10b5-1 Trading Plan Adoptions in Amended Q1 2026 SEC Filing - Minichart
Crescent Biopharma Inc (CBIO) 財務データ
収益
当期純利益
現金流量
EPS
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):